A common, safe drug may significantly improve how cancer therapies work
At Dartmouth Cancer Center, researchers have found that telmisartan — a blood pressure medication taken by millions — may quietly hold a second vocation: amplifying the body's own capacity to recognize and destroy cancer. The drug appears to make tumors vulnerable to a class of targeted therapies even when those tumors lack the genetic defects that normally qualify patients for treatment, while also awakening immune responses that cancer has learned to suppress. It is a reminder that medicines, like people, sometimes carry gifts that go unrecognized for years — and that the boundary between treating one illness and another can be thinner than we imagined.
- PARP inhibitors, powerful cancer drugs, have long been locked behind a genetic gatekeeping requirement — most patients simply don't qualify, and those who do often develop resistance.
- Telmisartan breaks that gate open, making tumor cells susceptible to olaparib even without the DNA repair defects that normally define eligibility.
- The drug works on two fronts simultaneously: amplifying DNA damage in cancer cells while triggering immune-alerting interferons and stripping away PD-L1, the protein cancers use to hide from the immune system.
- Crucially, this effect appears unique to telmisartan — other drugs in the same blood pressure class showed none of the same cancer-fighting behavior.
- Two clinical trials are now enrolling patients — one in metastatic prostate cancer, one in platinum-resistant ovarian cancer — with the first prostate patient already showing an exceptional early response.
- The coming months will determine whether a cheap, oral, widely tolerated pill can redraw the boundaries of who benefits from some of oncology's most important therapies.
A team at Dartmouth Cancer Center has found that telmisartan, a common blood pressure medication, can meaningfully improve how well PARP inhibitors — a class of targeted cancer drugs — work against tumors. The research, led by Tyler J. Curiel and published in The Journal for ImmunoTherapy of Cancer, points toward a way to treat cancers that currently resist these therapies entirely.
PARP inhibitors like olaparib work by exploiting a vulnerability in cancer cells that carry mutations in DNA repair genes like BRCA. But this limits their reach: most patients lack those mutations, and even those who initially respond often develop resistance over time. Curiel's team set out to change that equation.
In preclinical studies, telmisartan — an angiotensin II receptor blocker — made tumor cells susceptible to olaparib even without the usual DNA repair defects. The mechanism operates on two levels: the combination increased DNA damage in cancer cells, and it triggered immune-stimulating signals, specifically boosting type I interferons while reducing PD-L1, the protein cancers use to evade immune detection. Notably, other drugs in the same blood pressure class did not produce these effects — telmisartan appears to be singular in this regard.
The drug's practical profile makes it an unusually attractive candidate for rapid clinical use. It is oral, inexpensive, well-tolerated, and can be taken safely by people without hypertension. Two clinical trials are now underway — one in metastatic, castration-resistant prostate cancer, one in platinum-resistant ovarian cancer — with early signals described as encouraging. The first prostate cancer patient enrolled showed what Curiel called an exceptional response.
If the trials confirm the preclinical findings, telmisartan could expand the population eligible for PARP inhibitor therapy and help overcome the resistance that limits these drugs over time. Curiel's team also has preliminary data suggesting similar benefits may extend to chemotherapy and immunotherapy in other cancer types. The next months will be decisive in determining whether a drug designed to lower blood pressure can reshape the treatment of some of oncology's most stubborn diseases.
A team at Dartmouth Cancer Center has discovered that telmisartan, a blood pressure medication taken by millions of people worldwide, can substantially improve how well a class of cancer drugs called PARP inhibitors work against tumors. The finding, published in The Journal for ImmunoTherapy of Cancer, emerged from research led by Tyler J. Curiel, MD, MPH, FACP, and suggests a path toward treating cancers that currently resist these targeted therapies.
PARP inhibitors like olaparib exploit a specific vulnerability in cancer cells—their inability to repair certain kinds of DNA damage. The drugs work best against tumors carrying mutations in genes like BRCA, which disrupt the cell's natural repair machinery. But this limits their usefulness. Many cancers lack these particular genetic defects, meaning most patients cannot benefit from PARP inhibitors at all. And even when tumors do respond initially, they often develop resistance over time, rendering the drug ineffective.
Curiel's team set out to change that equation. In preclinical studies, they found that telmisartan, an angiotensin II receptor blocker commonly prescribed for high blood pressure, made tumor cells vulnerable to olaparib even when those cells lacked the DNA repair defects that normally make PARP inhibitors effective. The mechanism appears to work on two fronts. First, the combination increased DNA damage in cancer cells. Second, and perhaps more importantly, it triggered a cascade of immune-stimulating signals. Specifically, telmisartan boosted production of type I interferons—molecules that alert the immune system to the presence of cancer and help it mount an attack. The drug also reduced levels of PD-L1, a protein that cancers use as a kind of invisibility cloak to hide from immune surveillance.
What makes this discovery particularly striking is that telmisartan appears to be unique among blood pressure medications in this regard. When the researchers tested other drugs in the same class, they did not see the same cancer-fighting effects. Telmisartan also has practical advantages that make it an attractive candidate for rapid clinical translation. It is taken by mouth, safe, well-tolerated, and inexpensive. People without high blood pressure can take it without significant side effects. "This study shows that a common, safe, tolerable, convenient, and inexpensive drug may significantly improve how well an important class of cancer therapies works," Curiel said.
The research has already moved into human testing. Two clinical trials are now underway. One is evaluating the combination in men with metastatic, castration-resistant prostate cancer—a form of the disease that has progressed despite hormone therapy. The first patient enrolled in that trial experienced what Curiel described as an exceptional response. A second trial is testing the approach in platinum-resistant ovarian cancer, which just enrolled its first patient. Curiel noted that the team has preliminary data suggesting telmisartan may also enhance the effectiveness of chemotherapy and immunotherapy in other cancer types through similar mechanisms.
The implications are substantial. If the clinical trials confirm what the preclinical work suggests, telmisartan could expand the population of patients eligible for PARP inhibitor therapy and help overcome the resistance that currently limits these drugs' long-term effectiveness. "Our goal is to determine whether this combination approach can help more patients benefit from greater effectiveness of PARP inhibitors and other cancer treatment classes and potentially overcome resistance to these drugs," Curiel said. The early signals from the ongoing trials have been encouraging, though it remains too soon to draw firm conclusions. The next months will be critical in determining whether a drug developed to control blood pressure can reshape how oncologists treat some of the most difficult cancers to manage.
Citações Notáveis
This study shows that a common, safe, tolerable, convenient, and inexpensive drug may significantly improve how well an important class of cancer therapies works.— Tyler J. Curiel, MD, MPH, FACP, lead researcher at Dartmouth Cancer Center
Telmisartan has several distinct anticancer effects that, together with targeted therapy, could make tumors more responsive to distinct types of treatments.— Tyler J. Curiel
A Conversa do Hearth Outra perspectiva sobre a história
Why does telmisartan work when other blood pressure drugs in the same class don't?
That's the question we're still working to fully answer. The mechanism appears to involve how telmisartan specifically interacts with the immune system and tumor cells—boosting interferon production and reducing that invisibility protein, PD-L1. But the fact that it's unique among ARBs suggests there's something distinct about its molecular structure or how it behaves in cancer cells that we're still unpacking.
So this isn't just about fixing DNA repair. It's about waking up the immune system.
Exactly. PARP inhibitors alone create DNA damage in cancer cells, but the tumor can still hide from the immune system. Telmisartan seems to remove that hiding place while also amplifying the immune alarm signals. It's a one-two punch.
How many patients could this potentially help?
That's the real question. Right now, PARP inhibitors only work well in maybe 10-15% of cancers because of those specific genetic defects. If telmisartan can make them work in tumors without those defects, you're talking about expanding eligibility dramatically. But we have to prove it in the clinic first.
The first prostate cancer patient had an exceptional response. What does that mean in practical terms?
It means the tumor shrank significantly, the patient tolerated the combination well, and there were no unexpected safety issues. One patient isn't a pattern, but it's encouraging enough that we're moving forward carefully with more enrollments.
Why hasn't anyone tried this before?
Telmisartan has been around for decades as a blood pressure drug. Nobody was looking at it as a cancer therapy because it wasn't designed for that. This is what we call drug repurposing—taking something we know is safe and asking whether it might work in a completely different disease. It's cheaper and faster than developing something from scratch.
What happens if resistance develops to this combination too?
That's the honest answer we don't have yet. But the fact that we're engaging multiple mechanisms—DNA damage, immune activation, and PD-L1 reduction—suggests it might be harder for tumors to develop resistance to all three at once. We'll find out as more patients go through the trials.